Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,473.47
(
0.37%
)
US TECH 100
28,612.40
(
0.11%
)
Dow Jones
50,579.70
(
0.58%
)
Brent Oil
101.17
(
0.00%
)
Bitcoin
77,540.77
(
0.69%
)
News Focus
News Focus

Replies to post #176171 on Biotech Values

Replies to #176171 on Biotech Values
icon url

caravon

03/28/14 6:47 PM

#176172 RE: linhdtu #176171

GILD has very few pts with cirrhosis in each of their PhIII HCV clinical trials to have any meaningful statistical value.

Marketing success very strongly depends on clinical trial designs.
icon url

DewDiligence

03/28/14 7:31 PM

#176173 RE: linhdtu #176171

It’s reasonable to assume that EASL will be the venue where GILD discloses: i) the cirrhotic subgroup data from ION-1 and ION-2; and ii) the GT1a/GT1b subgroup data from all three ‘ION’ studies.